Panelists discuss how trial data and practical considerations inform the nuanced choice between amivantamab–lazertinib and osimertinib in managing EGFR-mutant non–small-cell lung cancer (NSCLC) with CNS disease.
Jun Zhang, MD, PhD
Advertisement
Articles by Jun Zhang, MD, PhD
Panelists discuss how personalized molecular insights drive first-line therapy choices in EGFR-mutant NSCLC with complex metastatic profiles.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: FDA Approvals, Trial Updates, and ASH 2025 Previews
2
HMA/Venetoclax Is Superior to Intensive Chemo in Fit Patients With AML
3
BRUIN Final Analysis: Pirtobrutinib Durable in Post-Covalent BTK CLL/SLL
4
Chemo-Free Ponatinib/Blinatumomab Improves Survival in Ph+ ALL
5
